Onesource Specialty Pharma Shares Plunge 18% After Weak Q3 Results
Share Market
C
CNBC Awaaz•27-01-2026, 12:40
Onesource Specialty Pharma Shares Plunge 18% After Weak Q3 Results
- •Onesource Specialty Pharma shares plummeted over 18% following the release of its Q3 results, causing significant investor losses.
- •The primary reason for the decline was a delay in regulatory approval for Semaglutide in Canada, impacting revenue and profit.
- •Q3FY26 saw revenue drop 23% quarter-on-quarter to INR 290.34 crore, with EBITDA falling 84% to INR 17.322 crore.
- •Despite the weak quarter, management expressed confidence, citing strong underlying demand, continuous order book growth, and a new biosimilar player addition.
- •The company reiterated its FY28 guidance, projecting organic revenue of INR 40,000-50,000 crore and an EBITDA margin of 40%.
Why It Matters: Onesource Specialty Pharma faced an 18% stock crash due to delayed Semaglutide approval and weak Q3 results.
✦
More like this
Loading more articles...
